SNDX
Syndax Pharmaceuticals, Inc.
There isn't enough reported data to score SNDX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
SNDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SNDX's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SNDX PE Valuation
SNDX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
SNDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
SNDX has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
SNDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.36 | +$1.24 |
| Q2 2026 | -$2.51 | +$1.37 |
| Q1 2026 | -$2.79 | +$1.06 |
| Q4 2025 | -$3.29 | +$0.43 |
| Q3 2025 | -$3.60 | +$0.05 |
| Q2 2025 | -$3.88 | -$0.48 |
| Q1 2025 | -$3.85 | -$0.61 |
| Q4 2024 | -$3.72 | -$0.74 |
SNDX is still losing money, but less than at its worst: $2.36 per share over the past year, against $3.88 at its worst in mid-2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over SNDX on earnings quality, reporting a profit while its opponent remains loss making.
SNDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.3M | +82% |
| Q2 2026 | $72.8M | +92% |
| Q1 2026 | $64.9M | +224% |
| Q4 2025 | $68.7M | +795% |
| Q3 2025 | $45.9M | +267% |
| Q2 2025 | $38M | +985% |
| Q4 2021 | $126.6M | +33209% |
| Q3 2021 | $12.4M | +3165% |
SNDX has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +75 points |
| Q2 2026 | -55% | +128 points |
| Q1 2026 | -53% | +365 points |
| Q4 2025 | -91% | +1164 points |
| Q3 2025 | -125% | +591 points |
| Q2 2025 | -183% | +1938 points |
| Q1 2025 | -418% | N/A |
| Q4 2024 | -1255% | N/A |
SNDX's operating margin was −50% last quarter, up 75 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over SNDX on profitability, with a higher operating margin.
SNDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.3M | +$43.3M |
| Q2 2026 | -$30.3M | +$57.5M |
| Q1 2026 | -$50.3M | +$44.8M |
| Q3 2025 | -$70.5M | -$8.2M |
| Q2 2025 | -$87.8M | -$16.2M |
| Q1 2025 | -$95.2M | -$11.6M |
| Q3 2024 | -$62.3M | -$17.7M |
| Q2 2024 | -$71.6M | -$36.3M |
UNH has the stronger cash trend. Its trailing FCF is up 5.2% versus its history, compared with SNDX at up 4.7%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
SNDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +799K shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +29% | +19.9M shares |
| 5 years | +73% | +37.8M shares |
| Available history | +184% | +58.1M shares |
SNDX has 90M diluted shares, up 3.7% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over SNDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
SNDX Net Leverage
SNDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
SNDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 5.3 | Oversold |
SNDX's weekly RSI is 26 (oversold) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
SNDX PE vs Healthcare Sector
| Metric | SNDX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SNDX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
SNDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 32% below |
| 20 week MA | $17.8 | 46% below |
| 50 week MA | $19.8 | 52% below |
| 100 week MA | $16.6 | 42% below |
| 200 week MA | $18.4 | 48% below |
SNDX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over SNDX on trend strength, trading above more of its moving averages.
SNDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.94 | $24.2 | +171% |
| 2021 | $24.2 | $22.5 | -7.1% |
| 2022 | $22.5 | $24.3 | +8.1% |
| 2023 | $24.3 | $21.6 | -11% |
| 2024 | $21.6 | $12.8 | -41% |
| 2025 | $12.8 | $21.3 | +67% |
| 2026 YTD | $21.3 | $9.54 | -55% |
SNDX's yearly returns have swung widely, from +171% in 2020 to −41% in 2024. It's down 55% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over SNDX on returns for 2026, with the stronger performance.